Tryptamine Therapeutics Completes Dosing of First Subject in Obesity Study

MT Newswires Live11-22 10:39

Tryptamine Therapeutics (ASX:TYP) completed the dosing of the first subject in its phase 1b study of its lead asset, TRP-8803, in obese participants, according to a Friday filing with the Australian bourse.

TRP-8803 is an intravenous-infusion formulation containing psilocin, known for its ability to induce adaptive structural and functional changes within the brain, the filing said.

The first participant received the drug, safely progressed through treatment, and was discharged shortly after the dosing follow-up was completed, according to the filing. Two more study applicants will be given TRP-8803 in the coming weeks.

Tryptamine Therapeutics shares rose more than 2% in afternoon trade Friday.

Price (AUD): $0.05, Change: $+0.001, Percent Change: +2.22%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485408256?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-22 10:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2485408256","market":"sh","top_or_hot":-1,"title":"Tryptamine Therapeutics Completes Dosing of First Subject in Obesity Study","media":"MT Newswires Live","content":"<html><body><p> Tryptamine <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ASX:TYP) completed the dosing of the first subject in its phase 1b study of its lead asset, TRP-8803, in obese participants, according to a Friday filing with the Australian bourse.</p><p>TRP-8803 is an intravenous-infusion formulation containing psilocin, known for its ability to induce adaptive structural and functional changes within the brain, the filing said.</p><p>The first participant received the drug, safely progressed through treatment, and was discharged shortly after the dosing follow-up was completed, according to the filing. Two more study applicants will be given TRP-8803 in the coming weeks.</p><p>Tryptamine Therapeutics shares rose more than 2% in afternoon trade Friday.</p><p>Price (AUD): $0.05, Change: $+0.001, Percent Change: +2.22%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tryptamine Therapeutics Completes Dosing of First Subject in Obesity Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTryptamine Therapeutics Completes Dosing of First Subject in Obesity Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-22 10:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tryptamine Therapeutics (ASX:TYP) completed the dosing of the first subject in its phase 1b study of its lead asset, TRP-8803, in obese participants, according to a Friday filing with the Australian ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2485408256","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485408256","pubTimestamp":1732243196,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tryptamine Therapeutics  completed the dosing of the first subject in its phase 1b study of its lead asset, TRP-8803, in obese participants, according to a Friday filing with the Australian bourse.TRP-8803 is an intravenous-infusion formulation containing psilocin, known for its ability to induce adaptive structural and functional changes within the brain, the filing said.The first participant received the drug, safely progressed through treatment, and was discharged shortly after the dosing follow-up was completed, according to the filing. Two more study applicants will be given TRP-8803 in the coming weeks.Tryptamine Therapeutics shares rose more than 2% in afternoon trade Friday.Price : $0.05, Change: $+0.001, Percent Change: +2.22%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","AUD":"Audacy Inc.","LU0994945656.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) INC 2","BK7096":"制药","LENZ":"Therapeutics","TYP.AU":"Tryptamine Therapeutics Ltd","LU0426417589.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) INC","LU2238339852.HKD":"NINETY ONE GSF GLOBAL ENVIRONMENT \"A\" (HKD) ACC","LU0345774631.USD":"NINETY ONE GSF AMERICAN FRANCHISE \"A\" (USD) INC","LU1043141123.HKD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (HKD) INC 2","BK4125":"广播","LU0426412945.USD":"NINETY ONE GSF GLOBAL FRANCHISE \"A\" (USD) ACC"},"translate_title":"Tryptamine Therapeutics完成肥胖研究中首例受试者的给药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AUD":1,"LENZ":1,"TYP.AU":0.9},"content_text":"Tryptamine Therapeutics (ASX:TYP) completed the dosing of the first subject in its phase 1b study of its lead asset, TRP-8803, in obese participants, according to a Friday filing with the Australian bourse.TRP-8803 is an intravenous-infusion formulation containing psilocin, known for its ability to induce adaptive structural and functional changes within the brain, the filing said.The first participant received the drug, safely progressed through treatment, and was discharged shortly after the dosing follow-up was completed, according to the filing. Two more study applicants will be given TRP-8803 in the coming weeks.Tryptamine Therapeutics shares rose more than 2% in afternoon trade Friday.Price (AUD): $0.05, Change: $+0.001, Percent Change: +2.22%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485408256"}